Home Colorectal Cancer With KRAS breakthrough on the horizon, Amgen’s David Reese reflects on sotorasib’s...

With KRAS breakthrough on the horizon, Amgen’s David Reese reflects on sotorasib’s looming review date and murky future – Endpoints News

59
0

Kathy High has re-emerged in the gene therapy space just as unexpectedly as she left Spark Therapeutics close to a year ago.

Her newest title will be president, therapeutics at AskBio, the biotech “race horse” that Bayer has just bought for $2 billion cash to build a cell and gene therapy unit around.

On the surface, the circumstances are not unlike Spark, which was getting absorbed into Roche following a $4.3 billion buyout. High, 68, was credited for both steering Luxturna toward an approval for a rare inherited eye disease caused by mutations in the RPE65 gene, setting up gene therapy research in hemophilia A and leading a Phase I/II trial for hemophilia B.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 97,600+ biopharma pros reading Endpoints daily — and it’s free.



https://endpts.com/with-kras-breakthrough-on-the-horizon-amgens-david-reese-reflects-on-sotorasibs-looming-review-date-and-murky-future/

This site uses Akismet to reduce spam. Learn how your comment data is processed.